Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Symbioflor 2 in diarrhoea-predominant irritable bowel syndrome
DRKS00018965Phase 4Recruiting
- Sponsor
- Symbiopharm
- Start
- Nov 2019
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in irritable bowel syndrome (IBS) comparing Symbioflor 2 with Placebo (2 arms). Started Nov 2019; status: recruiting.
02
Drugs
Escherichia coli Symbio DSM 17252
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on DRKS00018965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00018965.